These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29687023)

  • 1. An exploratory clinical study of p38
    Scheltens P; Prins N; Lammertsma A; Yaqub M; Gouw A; Wink AM; Chu HM; van Berckel BNM; Alam J
    Ann Clin Transl Neurol; 2018 Apr; 5(4):464-473. PubMed ID: 29687023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
    Alam J; Blackburn K; Patrick D
    J Prev Alzheimers Dis; 2017; 4(4):273-278. PubMed ID: 29181493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease.
    Meng X; Li T; Wang X; Lv X; Sun Z; Zhang J; Su F; Kang S; Kim S; An SSA; Yu X; Zhang C; Wang H
    Alzheimers Res Ther; 2019 Oct; 11(1):89. PubMed ID: 31651358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.
    Forsberg A; Almkvist O; Engler H; Wall A; Långström B; Nordberg A
    Curr Alzheimer Res; 2010 Feb; 7(1):56-66. PubMed ID: 20205671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionating verbal episodic memory in Alzheimer's disease.
    Wolk DA; Dickerson BC;
    Neuroimage; 2011 Jan; 54(2):1530-9. PubMed ID: 20832485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia.
    Frings L; Spehl TS; Weber WA; Hüll M; Meyer PT
    J Nucl Med; 2013 Nov; 54(11):1909-14. PubMed ID: 24101684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of porcine liver decomposition product for 4 weeks enhances visual memory and delayed recall in healthy adults over 40 years of age: A randomized, double-blind, placebo-controlled study.
    Matsuda Y; Haniu H; Tsukahara T; Uemura T; Inoue T; Sako KI; Kojima J; Mori T; Sato K
    Exp Gerontol; 2020 Nov; 141():111064. PubMed ID: 32841683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study.
    Fernández-Matarrubia M; Matías-Guiu JA; Cabrera-Martín MN; Moreno-Ramos T; Valles-Salgado M; Carreras JL; Matías-Guiu J
    J Alzheimers Dis; 2017; 57(4):1251-1264. PubMed ID: 28304289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
    Tolboom N; van der Flier WM; Yaqub M; Koene T; Boellaard R; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    Neurology; 2009 Dec; 73(24):2079-85. PubMed ID: 20018636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer's disease.
    Köhler S; Black SE; Sinden M; Szekely C; Kidron D; Parker JL; Foster JK; Moscovitch M; Winocour G; Szalai JP; Bronskill MJ
    Neuropsychologia; 1998 Sep; 36(9):901-14. PubMed ID: 9740363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline.
    Sanabria A; Alegret M; Rodriguez-Gomez O; Valero S; Sotolongo-Grau O; Monté-Rubio G; Abdelnour C; Espinosa A; Ortega G; Perez-Cordon A; Gailhajanet A; Hernandez I; Rosende-Roca M; Vargas L; Mauleon A; Sanchez D; Martin E; Rentz DM; Lomeña F; Ruiz A; Tarraga L; Boada M;
    Sci Rep; 2018 Feb; 8(1):3828. PubMed ID: 29491481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
    Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
    Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
    Villemagne VL; Rowe CC; Barnham KJ; Cherny R; Woodward M; Bozinosvski S; Salvado O; Bourgeat P; Perez K; Fowler C; Rembach A; Maruff P; Ritchie C; Tanzi R; Masters CL
    Alzheimers Dement (N Y); 2017 Nov; 3(4):622-635. PubMed ID: 29201996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.